PBH — Prestige Consumer Healthcare Inc.
$47.80-3.36%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for PBH in the TickerWise workspace.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Company profile
- Sector: Healthcare
- Industry: Medical - Distribution
- Country: US
- Exchange: NYSE
- Employees: 600
- Website: https://www.prestigebrands.com
Latest SEC filings for PBH
Latest PBH news
- Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? Read article
- Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results Read article
- Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment Read article
- PBH vs. NEOG: Which Stock Is the Better Value Option? Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.